{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T07:41:00Z","timestamp":1768635660821,"version":"3.49.0"},"reference-count":31,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/501100004160","name":"Mazandaran University of Medical Sciences","doi-asserted-by":"publisher","award":["10557"],"award-info":[{"award-number":["10557"]}],"id":[{"id":"10.13039\/501100004160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["IDDT"],"published-print":{"date-parts":[[2021,5,20]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Meropenem standard doses are based on the minimum inhibitory concentration\nof sensitive pathogens and the pharmacokinetic parameter of not critically ill patients. We\ncompared the efficacy of high versus standard dose of meropenem in ventilator-associated pneumonia\n(VAP).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>24 out of 34 eligible patients were randomized to receive meropenem 3 g q8h (high dose\ngroup, 11 patients) or 2 g q8h (standard-dose group, 13 patients) as a 3h infusion. The primary outcome\nwas considered as clinical success that was defined as stable hemodynamic, improved sequential\norgan failure assessment (SOFA) score, stable or improved PaO2\/FiO2 after 7 days. Sputum\nculture was taken before the intervention.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Clinical success rate was not significantly different between the high and standard-dose\ngroup (54.5% vs. 38.5%, P= 0.431). There was a significant difference in the reduction of clinical\npulmonary infection score (CPIS) compared to a high dose to the standard group (P=0.038). SOFA\nscore declined significantly in the high dose group throughout the study (P=0.006). A shorter duration\nof VAP treatment was recorded in the high dose group (P=0.061). We did not observe any significant\nadverse event related to meropenem. Acinetobacter spp. (34.8%), Klebsiella spp. (32.6%)\nand Pseudomonas aeruginosa (19.5%) isolated more frequently from sputum cultures.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Treatment with the high dose of meropenem seems to be safe. However, it did not provide\na significantly higher clinical success rate in comparison with the standard dose, but could be\nconsidered as an appropriate empirical treatment in patients with severe infection due to reduction\nin SOFA and CPIS.\nThe trial protocol was registered with IRCT.ir (registration number IRCT2010010700 3014N19 in\nApril 2018).<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871526520666200227102013","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T04:25:48Z","timestamp":1583123148000},"page":"274-283","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Effectiveness of a High Dose Versus the Standard Dose of Meropenem in Ventilator-associated Pneumonia Caused by Multidrugresistant Bacteria: A Randomized, Single-blind Clinical Trial"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4401-4191","authenticated-orcid":true,"given":"Mahila","family":"Monajati","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Pharmaceutical Research Center, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahram","family":"Ala","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Pharmaceutical Research Center, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Aliyali","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, Department of Internal Medicine, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roya","family":"Ghasemian","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Razi Hospital, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Heidari","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Ahanjan","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siavash","family":"Moradi","sequence":"additional","affiliation":[{"name":"Education Development Center, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Sharifpour","sequence":"additional","affiliation":[{"name":"Toxoplasmosis Research Center, Iranian National Registry Center for Lophmaniasis (INRCL), Mazandaran University of Medical Sciences, PO Box 48471-91971, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojtaba","family":"Mojtahedzadeh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebrahim","family":"Salehifar","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Pharmaceutical Research Center, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"Torres A.","year":"2017","unstructured":"Torres A.; Niederman M.S.; Chastre J.; Ewig S.; Fernandez-Vandellos P.; Hanberger H.; Kollef M.; Li Bassi G.; Luna C.M.; Martin-Loeches I.; Paiva J.A.; Read R.C.; Rigau D.; Timsit J.F.; Welte T.; Wunderink R.; International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT). Eur Respir J 2017,50(3),1700582","journal-title":"Eur Respir J"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1017\/ice.2016.174","volume":"37","author":"Weiner L.M.","year":"2016","unstructured":"Weiner L.M.; Webb A.K.; Limbago B.; Dudeck M.A.; Patel J.; Kallen A.J.; Edwards J.R.; Sievert D.M.; Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014. Infect Control Hosp Epidemiol 2016,37(11),1288-1301","journal-title":"Infect Control Hosp Epidemiol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","volume":"370","author":"Magill S.S.","year":"2014","unstructured":"Magill S.S.; Edwards J.R.; Bamberg W.; Beldavs Z.G.; Dumyati G.; Kainer M.A.; Lynfield R.; Maloney M.; McAllister-Hollod L.; Nadle J.; Ray S.M.; Thompson D.L.; Wilson L.E.; Fridkin S.K.; Multistate point-prevalence survey of health care-associated infections. N Engl J Med Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team2014,370(13),1198-1208","journal-title":"N Engl J Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ijantimicag.2014.01.007","volume":"43","author":"Sader H.S.","year":"2014","unstructured":"Sader H.S.; Farrell D.J.; Flamm R.K.; Jones R.N.; Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents 2014,43(4),328-334","journal-title":"Int J Antimicrob Agents"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.5539\/gjhs.v8n11p112","volume":"8","author":"Ghasemian R.","year":"2016","unstructured":"Ghasemian R.; Ahanjan M.; Fatehi E.; Shokri M.; Prevalence and antibiotic resistance pattern of acinetobacter isolated from patients admitted in ICUs in Mazandaran, Northern Iran. Glob J Health Sci 2016,8(11),112","journal-title":"Glob J Health Sci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"Kalil A.C.","year":"2016","unstructured":"Kalil A.C.; Metersky M.L.; Klompas M.; Muscedere J.; Sweeney D.A.; Palmer L.B.; Napolitano L.M.; O\u2019Grady N.P.; Bartlett J.G.; Carratal\u00e0 J.; El Solh A.A.; Ewig S.; Fey P.D.; File T.M.; Restrepo M.I.; Roberts J.A.; Waterer G.W.; Cruse P.; Knight S.L.; Brozek J.L.; Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016,63(5),e61-e111","journal-title":"Clin Infect Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1128\/AAC.00294-06","volume":"51","author":"Li C.","year":"2007","unstructured":"Li C.; Du X.; Kuti J.L.; Nicolau D.P.; Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007,51(5),1725-1730","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"e00794","DOI":"10.1128\/AAC.00794-17","volume":"61","author":"Cojutti P.","year":"2017","unstructured":"Cojutti P.; Sartor A.; Righi E.; Scarparo C.; Bassetti M.; Pea F.; Population pharmacokinetics of high-dose continuous-infusion meropenem and considerations for use in the treatment of infections due to kpc-producing klebsiella pneumoniae. Antimicrob Agents Chemother 2017,61(10),e00794-e17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"Roberts J.A.","year":"2014","unstructured":"Roberts J.A.; Paul S.K.; Akova M.; Bassetti M.; De Waele J.J.; Dimopoulos G.; Kaukonen K.M.; Koulenti D.; Martin C.; Montravers P.; Rello J.; Rhodes A.; Starr T.; Wallis S.C.; Lipman J.; DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis DALI Study2014,58(8),1072-1083","journal-title":"Clin Infect Dis"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","volume":"37","author":"Roberts J.A.","year":"2009","unstructured":"Roberts J.A.; Lipman J.; Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009,37(3),840-851","journal-title":"Crit Care Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11318140-000000000-00000","volume":"49","author":"Udy A.A.","year":"2010","unstructured":"Udy A.A.; Roberts J.A.; Boots R.J.; Paterson D.L.; Lipman J.; Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010,49(1),1-16","journal-title":"Clin Pharmacokinet"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ijantimicag.2014.12.017","volume":"45","author":"Huttner A.","year":"2015","unstructured":"Huttner A.; Von Dach E.; Renzoni A.; Huttner B.D.; Affaticati M.; Pagani L.; Daali Y.; Pugin J.; Karmime A.; Fathi M.; Lew D.; Harbarth S.; Augmented renal clearance, low \u03b2-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study. Int J Antimicrob Agents 2015,45(4),385-392","journal-title":"Int J Antimicrob Agents"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.ijantimicag.2010.11.014","volume":"36","author":"Giamarellou H.","year":"2010","unstructured":"Giamarellou H.; Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents 2010,36(Suppl. 2),S50-S54","journal-title":"Int J Antimicrob Agents"},{"key":"ref=14","first-page":"1319","author":"Guglielmo B.J.","year":"2018","unstructured":"Guglielmo B.J.;  Applied Therapeutics: the Clinical Use of Drugs 2018,1319-1342","journal-title":"Applied Therapeutics: the Clinical Use of Drugs"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"e009956","DOI":"10.1136\/bmjopen-2015-009956","volume":"6","author":"Dickstein Y.","year":"2016","unstructured":"Dickstein Y.; Leibovici L.; Yahav D.; Eliakim-Raz N.; Daikos G.L.; Skiada A.; Antoniadou A.; Carmeli Y.; Nutman A.; Levi I.; Adler A.; Durante-Mangoni E.; Andini R.; Cavezza G.; Mouton J.W.; Wijma R.A.; Theuretzbacher U.; Friberg L.E.; Kristoffersson A.N.; Zusman O.; Koppel F.; Dishon Benattar Y.; Altunin S.; Paul M.; Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open AIDA consortium2016,6(4),e009956","journal-title":"BMJ Open"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.rmedc.2009.09.011","volume":"3","author":"Bulik C.C.","year":"2010","unstructured":"Bulik C.C.; Quintiliani R.; Pope J.S.; Kuti J.L.; Nicolau D.P.; Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis\u2013A review of 3 cases. Respir Med CME 2010,3(3),146-149","journal-title":"Respir Med CME"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1128\/AAC.06389-11","volume":"56","author":"Taccone F.S.","year":"2012","unstructured":"Taccone F.S.; Cotton F.; Roisin S.; Vincent J-L.; Jacobs F.; Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 2012,56(4),2129-2131","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=18","author":"Pea F.","year":"2016","unstructured":"Pea F.; Della Siega P.; Cojutti P.; Sartor A.; Crapis M.; Scarparo C.; Might real-time pharmacokinetic\/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? Int J Antimicrob Agents 2016","journal-title":"Int J Antimicrob Agents"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","volume":"36","author":"Horan T.C.","year":"2008","unstructured":"Horan T.C.; Andrus M.; Dudeck M.A.; CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008,36(5),309-332","journal-title":"Am J Infect Control"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1227\/NEU.0000000000001432","volume":"80","author":"Carney N.","year":"2016","unstructured":"Carney N.; Totten A.M.; O\u2019Reilly C.; Ullman J.S.; Hawryluk G.W.J.; Bell M.J.;  Neurosurg 2016,80(1),6-15","journal-title":"Neurosurg"},{"key":"ref=21","year":"2017","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 71  xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.eucast.org\">http:\/\/www.eucast.org2017","journal-title":"Version 71"},{"key":"ref=22","year":"2009","unstructured":"Services H. Common terminology criteria for adverse events (CTCAE) version 4.0. J Natl Cancer Inst Health UDo2009","journal-title":"J Natl Cancer Inst"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13054-017-1755-5","volume":"21","author":"Weiss E.","year":"2017","unstructured":"Weiss E.; Essaied W.; Adrie C.; Zahar J-R.; Timsit J-F.; Treatment of severe hospital-acquired and ventilator-associated pneumonia: a systematic review of inclusion and judgment criteria used in randomized controlled trials. Crit Care 2017,21(1),162","journal-title":"Crit Care"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","volume":"18","author":"Paul M.","year":"2018","unstructured":"Paul M.; Daikos G.L.; Durante-Mangoni E.; Yahav D.; Carmeli Y.; Benattar Y.D.; Skiada A.; Andini R.; Eliakim-Raz N.; Nutman A.; Zusman O.; Antoniadou A.; Pafundi P.C.; Adler A.; Dickstein Y.; Pavleas I.; Zampino R.; Daitch V.; Bitterman R.; Zayyad H.; Koppel F.; Levi I.; Babich T.; Friberg L.E.; Mouton J.W.; Theuretzbacher U.; Leibovici L.; Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 2018,18(4),391-400","journal-title":"Lancet Infect Dis"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1164\/ajrccm.162.2.9909095","volume":"162","author":"Singh N.","year":"2000","unstructured":"Singh N.; Rogers P.; Atwood C.W.; Wagener M.M.; Yu V.L.; Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000,162(2 Pt 1),505-511","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1378\/chest.125.5.1791","volume":"125","author":"Micek S.T.","year":"2004","unstructured":"Micek S.T.; Ward S.; Fraser V.J.; Kollef M.H.; A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004,125(5),1791-1799","journal-title":"Chest"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/00003246-200106000-00003","volume":"29","author":"Ibrahim E.H.","year":"2001","unstructured":"Ibrahim E.H.; Ward S.; Sherman G.; Schaiff R.; Fraser V.J.; Kollef M.H.; Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001,29(6),1109-1115","journal-title":"Crit Care Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1093\/jac\/dky370","volume":"73","author":"Burger R.","year":"2018","unstructured":"Burger R.; Guidi M.; Calpini V.; Lamoth F.; Decosterd L.; Robatel C.; Buclin T.; Csajka C.; Marchetti O.; Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. J Antimicrob Chemother 2018,73(12),3413-3422","journal-title":"J Antimicrob Chemother"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1128\/AAC.02109-13","volume":"58","author":"Luyt C-E.","year":"2014","unstructured":"Luyt C-E.; Aubry A.; Lu Q.; Micaelo M.; Br\u00e9chot N.; Brossier F.; Brisson H.; Rouby J.J.; Trouillet J.L.; Combes A.; Jarlier V.; Chastre J.; Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother 2014,58(3),1372-1380","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2165\/00002018-200730080-00002","volume":"30","author":"Linden P.","year":"2007","unstructured":"Linden P.; Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Saf 2007,30(8),657-668","journal-title":"Drug Saf"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/00365549950161808","volume":"31","author":"Norrby S.R.","year":"1999","unstructured":"Norrby S.R.; Gildon K.M.; Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis 1999,31(1),3-10","journal-title":"Scand J Infect Dis"}],"container-title":["Infectious Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/179792","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/179792\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/179792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T14:29:50Z","timestamp":1634480990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/179792\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5,20]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871526520666200227102013","relation":{},"ISSN":["1871-5265"],"issn-type":[{"value":"1871-5265","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}